EGFR and lung adenocarcinoma: Actually, they represent about 80–85% of the total cases of EGFR mutation-positive lung adenocarcinoma (ADC) patients (patients with mutations located in the tyrosine kinase domain of the aforementioned gene) and they have a high sensitivity to EGFR-TKIs [3,4].